In short
Clinical trials are investigating SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER in studies of COVID-19 vaccination. These trials mainly look at immune response, safety-related study outcomes, and how well different vaccine products work in adults. The available trial data here includes a Phase 3 study in people receiving COVID-19 vaccines.
Key points
- Clinical trials investigating SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER are focused on COVID-19 vaccination research. The available study is a Phase 3 interventional trial with 4,000 participants. It compares different vaccine products and looks at immune response after vaccination. The main outcome is the share of people with antibody levels above a target level 6 months after two doses. The study is listed as completed and targets people in the setting of COVID-19 infection.
Trial overview
The available clinical trial is titled COVID-19 vaccine immunology and is listed as completed. It studies COVID-19 infection and looks at immune responses after vaccination with different vaccine formulations.
Study design and phase
This was an interventional study, which means researchers gave vaccine products and then measured the results. The trial was in Phase 3, a later stage of clinical testing that usually includes a larger number of people and checks how well a vaccine response performs.
The study planned to enroll 4000 participants.
Who the study involved
The trial data describes vaccine recipients in the setting of COVID-19 infection. The source material does not provide a full list of eligibility rules, so only the trial-level target population can be stated here.
Main outcome measured
The main outcome was the proportion of seropositive subjects with an antibody level above the target level at 6 months after two doses against the prevailing virus variant. In simple terms, the researchers wanted to see how many people had antibodies in their blood and whether those antibody levels reached the planned target.
Vaccines studied in the trial
The study compared several COVID-19 vaccine products, including BIMERVAX LP.8.1, Spikevax bivalent Original/Omicron BA.1, Comirnaty, Spikevax 50 micrograms, Comirnaty JN.1, Nuvaxovid, COVID-19, VIRAL VECTOR, NON-REPLICATING, Comirnaty Original/Omicron BA.4-5, Comirnaty Omicron XBB.1.5, and Comirnaty LP.8.1. All were given by injection into a muscle.
What the results mean for patients
This trial was designed to compare immune responses after different vaccine formulations, not to describe long-term disease treatment. The key patient-focused question is whether a vaccine product can help more people reach the target antibody level after vaccination. Because the study is completed, it adds evidence about how these vaccines performed in the tested group.